Interleukin-1 (IL-1) induces IL-1, tumor necrosis factor a (TNFa), and IL-6 gene expression and synthesis in a variety of cells. In this study, we investigated the ability of human recombinant IL-1 receptor antagonist (IL-lra) to inhibit IL-1-induced cytokine production in human peripheral blood mononuclear cells (PBMC) and isolated monocytes. IL-lra alone at concentrations as high as 1 pg/mL did not induce IL-la, IL-lp, TNFa, or IL-6 synthesis. Suppression of IL-1-induced IL-1, TNFa, or IL-6 synthesis was dose-dependent (P S .0001). At a twofold molar excess, IL-lra inhibited IL-1-induced IL-1 or TNFa synthesis by 50% (P < .Ol); an equimolar concentration of IL-lra inhibited synthesis of these two cytokines by over 20% (P < .05). A 10-fold molar excess of IL-lra over IL-lp reduced IL-lpinduced IL-la by 95% (P = .01) and IL-la-induced IL-1p by 73% (P < .01).
By Eric V. Granowitz, Burton D. Clark, Edouard Vannier, Michael V. Callahan, and Charles A. Dinarello Interleukin-1 (IL-1) induces IL-1, tumor necrosis factor a (TNFa), and IL-6 gene expression and synthesis in a variety of cells. In this study, we investigated the ability of human recombinant IL-1 receptor antagonist (IL-lra) to inhibit IL-1-induced cytokine production in human peripheral blood mononuclear cells (PBMC) and isolated monocytes. IL-lra alone at concentrations as high as 1 pg/mL did not induce IL-la, IL-lp, TNFa, or IL-6 synthesis. Suppression of IL-1-induced IL-1, TNFa, or IL-6 synthesis was dose-dependent (P S .0001). At a twofold molar excess, IL-lra inhibited IL-1-induced IL-1 or TNFa synthesis by 50% (P < .Ol); an equimolar concentration of IL-lra inhibited synthesis of these two cytokines by over 20% (P < .05). A 10-fold molar excess of IL-lra over IL-lp reduced IL-lpinduced IL-la by 95% (P = .01) and IL-la-induced IL-1p by 73% (P < .01).
IL-lra added to PBMC 8 hours after stimulation with IL-lp was still able to inhibit IL-la, TNFa, and IL-6 synthesis NTERLEUKIN-la (IL-la) and IL-1p are two distinct I gene products that have 25% amino acid similarity, recognize both IL-1 receptors (IL-lR), and exert similar biologic effects. Synthesis of acute-phase proteins, fibroblast proliferation, and T-cell activation take place when IL-1 binds to the IL-1R type I (IL-lRtI).I IL-1 is also capable of inducing its own gene expression and synthesis in several cell types, including fibroblasts,2 endothelial cells,3 and smooth muscle cells. 4 This effect of IL-1 is thought to be due to triggering of the IL-1RtI. In peripheral blood mononuclear cells (PBMC), IL-1 can also induce production of IL-1: tumor necrosis factor u (TNFa): and IL-6.7 Isolated monocytes have been shown to be the source of these cytokines? It has been assumed that the biologic activity of IL-1 is exerted via the IL-1RtI despite the fact that monocytes may not express IL-1RtI. Recently, Spriggs et a19 have shown that human monocytes express a 63-Kd IL-1R type I1 (IL-1RtII) that is immunologically distinct from the IL-1RtI.
The IL-1 receptor antagonist (IL-lra) is a 22-Kd glycoprotein that inhibits the binding of IL-1 to the IL-1RtI on T cells1°-12 as well as the IL-1RtII on polymorphonuclear leukocytes (PMN) and B ~el1s.l~ IL-lra has 19% amino acid similarity with IL-la and 26% amino acid similarity with (P 5 .01). A similar reduction in IL-lp-induced IL-la was observed when IL-lp was removed from the cultures after 8 hours of stimulation (P < .05), suggesting a prolonged presence of IL-1 or restimulation of IL-1 receptors on monocytes is required for the induction of cytokines. In elutriated monocytes, a 10-fold molar excess of IL-lra reduced IL-lpinduced IL-la by 82% (P < .05), TNFa by 64% (P = .05), and IL-6 by 47% (P < .05). 1251-IL-lp was bound to purified monocytes, cross-linked, and immunoprecipitated. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis showed a band at 85 Kd corresponding to the 68-Kd IL-1 receptor type II (IL-1RtIl). Excess unlabeled IL-lp or IL-lra blocked the binding of 1251-IL-1p to the IL-1Rtll. We conclude that IL-lra inhibits IL-l-induced cytokine synthesis and competes with IL-1 for the IL-1Rtll on human monocytes. 0 1992 by The American Society of Hematology.
IL-lp.14 Despite this amino acid similarity with IL-1, IL-lra has no agonist activity.15J6 However, IL-lra does inhibit IL-lp-induced synthesis of prostaglandin &(PGE,) by fibroblasts expressing the IL-1RtI.I1 However, there are no data showing IL-lra can block IL-1-induced protein synthesis in a cell possessing the IL-1RtII.
In the present studies, we showed that IL-lra inhibits IL-1-induced IL-1, TNFu, and IL-6 production in PBMC. Because Leu M3+ cells are the primary source of IL-1 in PBMC, 8 we also determined that IL-lra reduced IL-1, TNFa, and IL-6 production by isolated monocytes. We used cross-linking of 1251-IL-l p to purified monocytes to show that IL-lra recognized the IL-lRtII on these cells.
MATERIALS AND METHODS

IL-1 and other reagents.
Human recombinant IL-la was the gift of Dr Peter Lomedico (Hoffmann-LaRoche, Nutley, NJ). Human recombinant IL-lp was kindly donated by Dr Aldo Tagliabue (Sclavo Research Centre, Siena, Italy). These cytokines contained less than 100 pg/mg of endotoxin as determined by the Limulus amebocyte lysate test (Associates of Cape Cod, Woods Hole, MA). Human recombinant IL-lra was provided by Dr Robert C. Thomp- son (Synergen Inc, Boulder, CO). Radiolabeling of IL-lp with lxI (New England Nuclear, Boston, MA) was performed using chloramine T (Sigma Chemical Co, St Louis, MO).
RPMI 1640 (Sigma) containing 10 mmol/L L-glutamine, 24 mmol/L NaHC03 (Mallinckrodt, Paris, KY), 10 mmol/L HEPES (Sigma), 100 U/mL penicillin, and 100 &mL streptomycin (Imine Scientific, Santa Ana, CA), pH 7.4, was ultrafiltered using polysulfone hollow fiber filters (F40; Fresenius AG, Bad Homburg, Germany) to remove substances capable of inducing cytokine prod~ction.'~ The binding assay buffer consisted of bovine serum albumin (BSA; 1% final concentration, Fraction V, Sigma) in ultrafiltered RPMI with 20 mmoliL HEPES, pH 7.2. Human AB serum was heat-inactivated for 45 minutes at 56°C. Indomethacin (Sigma) was dissolved in 95% ethanol at 10 mg/mL. CHAPS lysis buffer (CLB) was made by adding 1% wtlvol CHAPS (Sigma) and 2 mmol/L phenylmethylsulfonyl fluoride (Sigma) to phosphatebuffered saline (PBS).
PBMC were prepared from healthy human volunteers who had not used cyclooxygenase inhibitors Human PBMC cultures. water containing less than 100 pg/mL of endotoxin. PBMC were washed twice in sterile 0.9% sodium chloride (Abbott Laboratories, North Chicago, IL) before being resuspended at a concentration of 5 x lo6 cells/mL in RPMI. The cell suspension was supplemented with 2% vol/vol heat-inactivated AB serum and 1 pg/mL indomethacin. PBMC (500 pL) were then aliquoted into 5-mL polypropylene tubes and the tubes placed in a 37°C water bath. Fifteen minutes later, 250 p L of either RPMI or IL-lra in RPMI was added (except as indicated). Cells were incubated an additional 30 minutes in the 37°C water bath. At that time 250 pL of either RPMI or IL-1 in RPMI was added. All cells were then incubated for 24 hours (unless stated otherwise) at 37°C in a humidified atmosphere containing 5% C02. After incubation, PBMC cultures were immediately frozen at -70°C (unless separated).
Where indicated, IL-1p was removed from the cultures at specific times. Cell suspensions were centrifuged at 50g for 5 minutes; supernatants were removed and frozen at -70°C. Cell counts performed on these supernatants showed less than 4% of the original number of PBMC. Supernatants were replaced by an equivalent volume of RPMI with 1% AB serum that had been maintained at 37°C under identical conditions. In these same experiments, PBMC were again separated from the cultures before freezing. Cell suspensions were centrifuged at 30% for 5 minutes; supernatants were removed and frozen at -70°C. Cell pellets were washed once with RPMI, resuspended in 1 mL RPMI with 1% AB serum, and then frozen at -70°C.
PBMC cultures or PBMC pellets were subjected to three freeze-thaw cycles to yield maximal recovery of cell-associated cyt~kines.'~ Samples were assayed in duplicate for IL-la," IL-lp?l TNFa," or IL-67 by radioimmunoassay (RIA). Previous studies have shown no cross-reactivity between these RIA. The limit of detection for each RIA was 40 to 80 pg/mL IL-la, 80 to 160 pg/mL IL-lp, 80 to 160 pg/mL TNFa, and 80 to 160 pg/mL IL-6. In addition, IL-lra (1 pg/mL) was added to each tube of IL-la RIA standards (20 pgimL to 10 ng/mL). Inhibition of IL-la binding in its RIA was unaffected by the presence of IL-lra. A similar experiment showed the binding of IL-1p was not affected by the presence of IL-lra (data not shown).
PBMC were incubated in PBS (Sigma) with mouse antihuman Leu M3 monoclonal antibody (MoAb;
Becton Dickinson, Mountain View, CA) for 30 minutes at 4"C, washed in PBS, and then incubated with magnetic microspheres at 10 rpm for 2 hours at 4"C?3 Magnetic microspheres (Dynabeads M-280 sheep antimouse IgG; Dynal Inc, Great Neck, NY) were precoated with affinity-purified, sheep polyclonal IgG against all mouse IgG subclasses. Leu M3+ cells attached to the microspheres were then separated from Leu M3-cells with a magnet. Leu M3+ cells were resuspended in PBS and rotated for 1 additional hour at 4°C. The Leu M3+ cells were once again pelleted with a magnet before removing the supernatant. PBMC (treated in the same manner as Leu M3-cells except for the addition of Leu M3 MoAb and microspheres), Leu M3+ cells, and Leu M3-cells were resuspended separately in RPMI with 2% AB serum and 1 pg/mL indomethacin. Experiments as described above for stimulating human PBMC were then performed. Fluorescence-activated cell sorter (FACS) analysis (Epic 4; Coulter Electronics, Hialeah, FL) of a representative of two experiments showed that the unfractionated PBMC contained 10% Leu M3+ cells.
Magnetic microspheres.
Elutriation. Monocytes were separated from total PBMC by countercurrent centrifugal elutriation (J-6B centrifuge, elutriation rotor, 20-mL elutriation chamber; Beckman Instruments Inc, Fullerton, CA) as described by Stevenson.24 PBMC were gently agitated to achieve a single cell suspension before being resuspended at a concentration of 1 x lo7 cells/mL in RPMI with 0.25% AB serum at 4°C. PBMC were then loaded at a flow rate of 5.25 mL/min into an elutriator maintained at 4°C and 56%. While the flow rate was kept constant, centrifugation speed was decreased to 49%. Subsequently, flow rate was increased by 500 p,L/min every 10 minutes. Cell fractions were collected in 50-mL aliquots and stored at 4°C until quantitation. As determined by staining with a-naphthylacetate esterase (Sigma) and Diff-Quik (Baxter Scientific Products, McGaw Park, IL), the populations designated 'monocytes' contained 93% to 97% monocytes. Viability of monocytes was greater than 99%, as determined by trypan blue exclusion and phagocytosis of latex beads. Those populations labeled 'lymphocytes' contained 87% to 97% lymphocytes, as determined by Diff-Quik staining. Viability of lymphocytes was greater than 99%, as determined by trypan blue exclusion. In some experiments, monocytes and lymphocytes were washed twice before being resuspended in RPMI with 2% AB serum and 1 pg/mL indomethacin. Cells were stimulated as described for human PBMC.
Raji cells were obtained from American Type Culture Collection (Rockville, MD). EL4-6.1 cells were a kind gift of Dr Robert Newton (E.I. du Pont de Nemours & Co, Glenolden, PA). Both cell lines were cultured in RPMI containing 5% FCS.
Cross-linking of 1251-IL-lp to IL-IR Using the methods of Sprigs et a1,9 elutriated monocytes were suspended at 5 x lo6 cells/mL in RPMI with 1% AB serum and mol/L dexamethasone. The monocytes were then incubated for 12 hours at 37°C. Subsequently, the monocytes were centrifuged at 300g for 10 minutes. The cell pellet was then resuspended for 1 minute at 4°C in 500 pL of 150 mmol/L sodium chloride, 100 mmol/L glycine HCl, pH 3.2 before being diluted to 50 mL in PBS (4°C).
Monocytes, Raji cells, and EL4-6.1 cells were washed twice in cold RPMI before being resuspended in binding buffer. Either 25 x lo6 monocytes, 8 x lo6 Raji cells, or 20 x lo6 EL4-6.1 cells were then rotated at 10 rpm at 4°C overnight with 1 nmol/L 1251-IL-lp in the presence of either 1 pmol/L IL-lp or 100 pmol/L IL-lra. The final volume was 1 mL. Cells were then washed with cold PBS and cross-linked in the presence of 2.7 mmol/L bis(su1fo-succinimidy1)suberate (Pierce, Rockford, IL) for 2 hours at 4°C. After a wash with cold PBS, the cells were lysed in CLB. After 30 minutes on ice, cell debris was removed by centrifugation at 13,OOOg for 15 minutes at 4°C.
Using the methods of Rangnekar et alZ and Clark et a1,26 rabbit antihuman IL-lp antibodyz1 was used to precipitate the solubilized IL-lp/IL-lR complexes. Briefly, 100 pL of packed IgGSorb (The Enzyme Center, Malden, MA) was incubated with 50 pg of affinity-purified goat antirabbit IgG (Southern Biotechnology Associates, Birmingham, AL) at 10 rpm for 6 hours at 4°C. After washing twice in CLB, the conjugated IgGSorb was resuspended in 1 mL cold PBS. Aliquots of 216 p L conjugated IgGSorb were then mixed with 24 pL rabbit antihuman IL-1p and incubated at 10 rpm overnight at 4°C. The antihuman IL-lp-conjugated IgGSorb was washed twice with CLB before being resuspended in 160 pL CLB. Before immunoprecipitation, cell lysates were incubated for 30 minutes on ice with 10 pL of IgGSorb conjugated with goat antirabbit IgG to remove nonspecific binding proteins. Monocytes, Raji cells, and EL4-6.1 cell lysates were combined with 14 pL of antihuman IL-lp-conjugated IgGSorb and then incubated at 10 rpm overnight at 4°C. Immunoprecipitates were pelleted by centrifugation at 13,OOOg for 15 Cel/ culture.
Immunoprecipitation.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From Statistical analysis was performed using the Student's t-test for paired samples and analysis of variance using Fischer's least significant difference. Data are expressed as mean f standard error of the mean (SEM).
RESULTS
Statistics.
IL-lra does not induce IL-la, IL-lB TNFa, or IL-6 production by PBMC. In PBMC from nine donors, there was less than 100 pg/mL of IL-la, IL-lp, or IL-6 in either the untreated or IL-lra-treated (10 ng/mL to 1 pg/mL) samples. The concentration of TNFa in untreated PBMC cultures (414 f 102 pg/mL) did not significantly differ (P = .53) from the TNFa produced by PBMC treated with 1 pg/mL IL-lra (458 2 13 pg/mL).
IL-lra inhibits IL-linduced IL-1 production in PBMC. In the present study we investigated whether IL-lra could interfere with IL-1-induced IL-1 production in PBMC. PBMC from four donors were precultured with or without IL-lra. The cellswere then stimulatedwith IL-lp (Fig 1) . A 10-fold molar excess of IL-lra over IL-lp resulted in a 95% reduction in IL-la synthesis (P = .01). Pretreatment with IL-lra (Fig 1) also resulted in a 73% reduction in IL-lainduced IL-lp synthesis (P < .01). Because IL-lra blocks IL-1-induced PGE, synthesis,,' we added indomethacin to these cultures. The presence of indomethacin (1 pg/mL) did not modify the amount of inhibition by IL-lra (data not shown). Inhibition of IL-lenduced IL-la and TNFa by IL-lra is dose-dependent. The preceding data showed that IL-1 pinduced cytokines can be inhibited by a 10-fold molar excess of IL-lra. PBMC from four donors were incubated in the presence of increasing concentrations of IL-lra. All samples were then stimulated with IL-lp (Fig 2A) . IL-lra suppressed IL-lp-induced IL-la by over 20% (P < .OS) at an equimolar ratio of IL-lra to IL-1p. A twofold molar excess of IL-lra over IL-lp inhibited IL-la synthesis by 50% (P < .01). Similar concentrations of IL-lra had the same effect of IL-lp-induced TNFa (P < .01) (Fig 2B) . to inhibit IL-6 synthesis by 50% (P < .05) (Fig 2C) .
Inhibition of IL-lp-induced IL-6 by IL-lra was also dose-
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IL-lra INHIBITS IL-1-INDUCED CYTOKINES
Addition of IL-lra simultaneously or after stimulation with IL-lp reduces synthesis of IL-la, TNFa, and IL-6. In the preceding experiments, IL-lra was added 30 minutes before stimulation of PBMC with IL-1p. We next chose to address whether IL-lra added concurrently with or subsequent to IL-1p could still inhibit IL-1P-induced cytokine production. PBMC from four donors were treated with IL-lra either 30 minutes before, at the same time, or at 4,8, or 24 hours after stimulation with IL-1p. Cells were incubated at 37°C for 48 hours after the addition of IL-1p. IL-lra added before or concurrent with IL-1p resulted in 90% inhibition of IL-lp-induced IL-la (P < .001) (Fig 3) .
IL-lra added to PBMC either 4 or 8 hours after IL-1p
inhibited IL-la synthesis by 84% (P < .001) and 73% (P = .Ol), respectively. Adding IL-lra 24 hours after IL-1p did not inhibit the production of IL-la.
IL-lra added to PBMC either before or at the same time as stimulation with IL-lp resulted in greater than 75% inhibition of TNF synthesis (P = .001). Treating PBMC with IL-lra 8 hours after stimulation with IL-lp also resulted in 46% (P = .
001) inhibition of TNFa synthesis (data not shown). Similar data was obtained for inhibition of IL-lp-induced IL-6 by IL-lra (data not shown).
Removal of IL-Ipfrom the culture media reduces synthesis of cell-associated I L -l a The results of the previous experiments show that IL-1 at a concentration several orders of magnitude greater than that sufficient to occupy all IL-1R on PBMC could be displaced after 8 hours and still reduce IL-1 @induced cytokines. These observations suggested that IL-1R on PBMC require prolonged occupancy by IL-1 to transmit a signal that stimulates the synthesis of IL-1, TNFa, and IL-6. Therefore, we removed IL-1p at different times from the PBMC cultures and assessed cytokine synthesis. Five minutes, 1,4,8, or 24 hours after stimulation with IL-1P, the culture media containing IL-lp was replaced with RPMI containing 1% AB serum. After 48 hours of culture, PBMC were isolated and cell-associated IL-la o l . , . , . , . l . , . l . , . , . , Time of IL-1 ra addition (hour) o ! . , . , . , . , . , . , . , . I . , hours were all less than 50 pg/mL. To control for any contribution of centrifugation to these results, parallel cultures were centrifuged at the specified times. PBMC were then resuspended in the same IL-1p containing media. Centrifugation did not significantly affect the synthesis of IL-la (data not shown).
IL-Ira inhibits IL-lp-induced IL-la in Leu M3+cells. Leu M3+ cells in the PBMC preparation are the primary source of IL-1.8 It is possible that IL-lra inhibits IL-1 by blocking the production of a T-cell product that induces monocytes to make IL-1. We used magnetic microspheres to separate Leu M3+ cells from the other cells in PBMC. PBMC, Leu M3+ cells, and Leu M3-cells were then cultured with or without IL-lra before being stimulated with IL-lp. As illustrated in Fig 5, 2 .5 x lo6 PBMC stimulated with IL-lp produced 4.2 ng/mL IL-la, whereas 2.5 x lo6 Leu M3+ cells stimulated with IL-1p produced 18 ng/mL IL-la. Leu M3-cells produced 950 pg/mL IL-la. Pretreatment of PBMC and Leu M3+ cells with IL-lra reduced IL-la production to 150 pg/mL and 800 pg/mL IL-la, respectively.
IL-Ira inhibits IL-lmnduced IL-la, TNFa, and IL-6 in elutriated monocytes. Monocytes and lymphocytes obtained by elutriation of PBMC from four donors were incubated in the presence or absence of IL-lra before being stimulated with IL-lp. Elutriated monocytes pretreated with IL-lra produced 82% less IL-la than untreated monocytes (P < .05) (Fig 6A) . Monocytes exposed to IL-lra exhibited a 64% reduction in IL-lp-induced TNFa (P = .05) (Fig 6B) . Monocytes pretreated with IL-lra before stimulation with IL-1P also produced 47% less IL-6 than untreated monocytes (P < .05) (Fig 6C) . Lymphocytes at a concentration of 2.5 X lo6 cells/mL produced less than 125 pg/mL IL-la, 975 2 225 pg/mL TNFa, and less than 500 pg/mL IL-6.
Binding of 12sI-IL-l/3 to the IL-1RtII on monocytes is inhibited by IL-lra.
We studied the possibility that IL-lra inhibits IL-1-induced cytokines by blocking binding to the IL-1RtII on human monocytes. Elutriated monocytes, Raji cells, and EL4-6.1 cells were incubated with 1251-IL-lp in the presence or absence of excess cold IL-lp or IL-lra. Subsequently, these cells were cross-linked, lysed, and immunoprecipitated using rabbit antihuman IL-1 p antibody before being analyzed by SDS-PAGE and autoradiography. As shown in Fig 7, cross- 
DISCUSSION
The data presented here show that IL-lra inhibits the induction of cytokines by IL-1 in human monocytes possessing the IL-IRtII. The natural human urine-derived IL-lra (formerly called the IL-1 inhibitor) had been shown to block the binding of IL-1 to type I-bearing murine EL4-6.1 thymoma cells.10 When we initiated these experiments, it was unclear whether IL-lra would block IL-1R on monocytes because studies had shown that the recombinant antagonist did not block the binding of IL-1 to the IL1RtII.11J2 Subsequent to these studies, we showed that IL-lra competively inhibited the binding of IL-la and IL-lp to the IL-1RtII on human PMN and Raji human B-lymphoma cells.13 However, in the present study, we investigated the effect of IL-lra using a functional parameter of the IL-1RtI1, ie, cytokine synthesis.
IL-lra did not itself induce IL-1, TNFa, or IL-6 synthesis in PBMC, supporting the concept that IL-lra does not possess agonist a~t i v i t y .~~J~ However, IL-1 p-induced IL-la was inhibited 95% by a 10-fold molar excess of IL-lra over IL-1p; IL-la-induced IL-1p was also inhibited (73% by a 10-fold excess of IL-ha). These differences may be attributable to the fact that IL-lra is a more potent inhibitor of IL-lp binding to the IL-1RtII. 13 In (lanes 1, 2, and 3). Raji cells (lanes 4, 5, and 6 ). or (lanes 7,8, and 9) were Incubated overnight at 4°C with 1 nmol/L 'nUL-lp alone (lanes 1, 4, and 7 ) or in the presence of 1 pmol/L IL-1p (lanes 2. 5, and 8) or 100 pmol/L IL-lra (lanes 3,6, and   9 ). After cross-linking, the IL-lg/lL-lR complex was immunoprecipitated with antUL-1p and then analyzed by SDS-PAGE.
ELdB.1 cells
kines by over 20%. In contrast, Arend et a127 found that a fivefold molar concentration of IL-lra was required to produce a 50% inhibition of IL-1p-induced murine thymocyte proliferation. Fifty percent inhibition of IL-lpinduced PGE, production in human synovial cells and rabbit chondrocytes required 14-fold and 78-fold molar excesses of IL-lra, respectively. In bovine nasal cartilage explants, 50% inhibition of ILla-induced PGE, synthesis required a 20-fold molar excess of IL-lra.% Seckinger et a129 needed concentration ratios of IL-lra to IL-1 of 10 to block bone resorption in fetal rat long bones by 50%. Carter et all2 reported that a ninefold molar excess of IL-lra was necessary for a 50% inhibition of IL-Ip-augmented endothelial cell adhesiveness for neutrophils.
The above studies using ILlRtI bearing cells are to be contrasted with the present studies using IL-1RtII-bearing cells. I L l r a may be a more potent inhibitor in monocytes due to differences between the IL-lRtI and the ILlRtII. For example, HorUkM has shown that binding, internalization, and intracellular localization differ for the ILlRtI and the ILlRtII.
Using monocytes isolated by either their Leu M3+ phenotype or elutriation, we observed that IL-lra inhibited IL1-induced cytokine production. Lymphocytes were not required. Although stationary monocytes cultured in 1% AB serum are a source of ILlra as well as IL1,3l it is unlikely that monocytes are downregulating IL-1 production in an autocrine fashion. Endogenous IL-lra does not significantly affect the minimal concentration of exogenous IL-Ira required to achieve maximal inhibition of lipopolysaccharide-induced cytokine synthesis?* Cross-linking studies confirmed that ILlra blocks '=I-I L l p binding to the human monocyte IL-1RtII. This finding was not unexpected; we have previously shown that IL-Ira can inhibit the binding of IL-1 to the IL-lRtII on human PMN and B-lymphoma cells.*3 In addition, Spriggs et a19 showed that the IL-lRtII was present on adherent human monocytes. While Spriggs et al did find messenger RNA (mRNA) encoding the IL-1RtI in human monocytes and THP-1 cells, neither their nor our cross-linking studies showed a band corresponding to the IL-1RtI. In murine macrophages, Chizzonite et a133 were unable to find mRNA encoding the ILlRtI.
The addition of IL-lra before or at the same time as IL-1p resulted in similar inhibition of IL-lp-induced cytokine synthesis. However, IL-lra also reduced IL-I& induced IL-la, TNFa, and IL-6 production even when the IL-lra was added 8 hours after stimulation with ILlf3. This was an unexpected observation. In PBMC treated with IGlf3, a similar reduction in IL-la synthesis was observed when IL-1p was removed from the cultures 8 hours after stimulation. Together, these observations suggest that the classical model of ligand-receptor signal triggering is different for IL-1 on these ILlRtII-bearing cells. Exposing 2.5 x 106 PBMC to 100 ng/mL IL-If3 results in lo9 IL-lp molecules per cell. Because human monocytes9 and lymphocytes% possess less than 103 IL-lR per cell, the conditions of our PBMC cultures represent over 106 molecules of IL-1s per IL-1R. Thus, prolonged exposure of IL-lR to saturating concentrations of IL-1 may be required to induce cytokine synthesis on these cells. Alternatively, constant restimulation of recycling IL-lR for 8 hours may be required for cytokine synthesis. In that case, in monocytes that have previously internalized the IL-1 /IL-1RtII complex, IL-lra may prevent IL-lp from binding to IL-lR that have recycled to the cell surface during the first 8 hours. This concept is supported by the recent finding that expression of the IL-lRtII on Raji cells is dependent on cell cycle with only 5% to 16% of cells expressing the receptor at any one time pointP5
An alternative explanation is that, during the first 8 hours of incubation with IL-1, IL-lR are expressed on a subpopulation of monocytes that did not possess surface receptors at the time of stimulation. IL-lra could then prevent binding of IL-1s to the newly expressed IL-1R. This explanation is supported by the fact that subpopulations of human monocytes respond differently to another cytokine, granulocyte-macrophage colony-stimulating factor."
Although our data show that IL-lra competitively inhibits the binding of I L l p to the ILlRtII on human monocytes, it does not exclude the possibility that human monocytes express both types of IL-1R. Human monocytes may be similar to human Bcell lines in expressing both IL-lRP7 Uhl et have found that elutriated human monocytes have a single class of receptors for IL-lf3 with a binding constant of 600 pmol/L and a receptor density of approximately 100 binding sites per cell. Cross-linking studies showed this monocyte IL-lR has the same molecular weight (80 Kd) as the IL-1RtI. Thus, it is possible that in human monocytes both I L l R are expressed and act cooperatively in signal transduction with small amounts of the IL-lRtI being required for the induction of cytokine synthesis. However, the requirement for prolonged exposure to IL-1 for the induction of cytokine synthesis, as shown in the present study, argues against a role for the IL-1RtI that induces protein synthesis after a short exposure to IL-1.
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